1. Home
  2. ABT vs VRTX Comparison

ABT vs VRTX Comparison

Compare ABT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABT

Abbott Laboratories

N/A

Current Price

$101.95

Market Cap

152.9B

Sector

Health Care

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$515.44

Market Cap

123.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ABT
VRTX
Founded
1888
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
152.9B
123.4B
IPO Year
2007
2006

Fundamental Metrics

Financial Performance
Metric
ABT
VRTX
Price
$101.95
$515.44
Analyst Decision
Strong Buy
Buy
Analyst Count
20
29
Target Price
$130.90
$539.69
AVG Volume (30 Days)
5.4M
945.9K
Earning Date
04-16-2026
05-04-2026
Dividend Yield
2.76%
N/A
EPS Growth
N/A
836.54
EPS
0.61
8.33
Revenue
$44,328,000,000.00
$2,488,652,000.00
Revenue This Year
$10.75
$10.79
Revenue Next Year
$8.10
$10.47
P/E Ratio
$172.54
$62.56
Revenue Growth
5.67
46.20
52 Week Low
$81.97
$374.17
52 Week High
$137.49
$560.25

Technical Indicators

Market Signals
Indicator
ABT
VRTX
Relative Strength Index (RSI) 35.99 44.26
Support Level $100.88 $425.34
Resistance Level $103.84 $533.67
Average True Range (ATR) 2.65 10.22
MACD -1.56 -5.20
Stochastic Oscillator 0.21 1.34

Price Performance

Historical Comparison
ABT
VRTX

About ABT Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: